

TRANSFORM LDL-C Risk to Identify High Risk Cardiovascular Disease Patients, Improve Access to Latest Cholesterol Lowering Treatments

New program will initiate real-world lipid management study to spur quality improvement

Congratulations! Your site is participating in [TRANSFORM LDL-C](#), a new initiative from the American College of Cardiology to identify high-risk patients with a history of cardiovascular events related to atherosclerotic cardiovascular disease (ASCVD) and to optimize their access to the latest evidence-based treatments for LDL-C lowering and cardiovascular event risk reduction.

Your site is part of a collaborative regional network of sites that can share best practices and influence future ACC work in this space. TRANSFORM LDL-C is the first of several planned TRANSFORM initiatives to turn ACC clinical algorithms and standards into actionable results for patients, while lowering the administrative barriers for clinicians and patients.

What is TRANSFORM LDL-C?

TRANSFORM LDL-C Risk will leverage the ACC's PINNACLE Registry – the largest cardiovascular outpatient clinical data registry – to identify patients with established ASCVD, many of whom will qualify as “very high risk” as defined by the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk and the 2018 ACC/AHA Guideline on the Management of Blood Cholesterol, in select sites across multiple regions in the U.S. and who meet the evidence-based criteria for enhanced treatments.

The ACC expert consensus decision pathway on non-statin therapies for LDL-C lowering in ASCVD management and the ACC/AHA cholesterol guideline focus on reducing CV events in patients with a history of ASCVD and who still have high LDL-C levels (above 70 mg/dL). Both the pathway and the guideline recommend considering non-statin drugs, including ezetimibe and PCSK9 inhibitors, for these patients who have residual risk.

ACC conducted an initial national study of current management of ASCVD patients across all PINNACLE practices, physician and patient characteristics, and their adherence to current ACC guidelines and clinical recommendations. Then, sites in specified regions with the largest patient populations currently eligible for additional lipid lowering therapy were engaged.

How Will Your Site Participate?

All participating sites will receive interventions ranging from patient centered medication initiation plans to clinician and patient education programs and self-assessment tools. An ACC quality ambassador will also provide on-the-ground support as needed to help with streamlining processes and addressing barriers to patient access to necessary therapies.

At the end of the program, the pre-determined list of quality variables, including medication adherence and physician prescribing patterns, will be evaluated with the goal of identifying factors that will drive action in high-risk patient cohorts, as well as inform the development of specific tools and resources that can reduce practice and physician pattern variations to break down barriers to care. The results of the real-world lipid management study will be published, with the ultimate goal being to share more broadly with hospitals, health systems and clinicians to help improve performance related to achieving optimal lipid management.

TRANSFORM LDL-C was developed through a partnership with ACC, Sanofi and Regeneron.